Development of a serum biosignature for ectopic pregnancy.
异位妊娠血清生物特征的开发。
基本信息
- 批准号:8846129
- 负责人:
- 金额:$ 66.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-05-07 至 2019-03-31
- 项目状态:已结题
- 来源:
- 关键词:Basic ScienceBeerBiological AssayBiological MarkersBloodCase-Control StudiesCause of DeathChorionic villiClinicalClinical ManagementCohort StudiesComplicationDevelopmentDiagnosisDiagnosticDiagnostic ProcedureDiagnostic testsDiscipline of obstetricsDiseaseEarly DiagnosisEctopic PregnancyEpidemiologyFailureFirst Pregnancy TrimesterGoalsGynecologyHealthHemorrhageHuman Chorionic GonadotropinInterruptionLocationMammalian OviductsMeasurementMedicineMethodologyMethodsMorbidity - disease rateOutcomePainPathway interactionsPerformancePhenotypePopulationPregnancyPregnant WomenPrenatal DiagnosisProceduresProcessProteomicsProtocols documentationPublic HealthResearchResourcesRiskRuptureSeriesSerumSpecimenSpontaneous abortionSymptomsTestingTranslatingUltrasonographyWomanbasebiosignatureclinical applicationclinically significantcorpus luteumimplantationimprovedmaternal morbiditymortalitymultidisciplinarynovel markerpatient populationprospectivereproductive
项目摘要
DESCRIPTION (provided by applicant): This is a revised application from a highly productive, multidisciplinary, multicenter project evaluating the diagnosis of women at risk for ectopic pregnancy (EP) and early pregnancy failure. Early pregnancy failure is the most common complication in pregnancy with an estimated 25% of clinically recognized pregnancies ending in miscarriage, and 1-2% are diagnosed as ectopic pregnancy (EP). EP is the leading pregnancy-related cause of death and a major contributor to maternal morbidity. When the gestation is not visible with ultrasound, distinguishing a healthy ongoing intrauterine gestation (IUP) from a miscarriage or an EP poses a critical clinical challenge as there is no other definitive, noninvasive diagnostic test. Current diagnostic protocols can result in the interruption of a desired IUP and/or morbidity associated with rupture of an EP. We have demonstrated that a number of putative biomarkers of EP can distinguish IUP from EP when used in combination. Using an unbiased proteomic analysis approach we have also established new biomarkers, one which we have already validated: ADAM-12. The goal of this project is to expand the use of biomarkers to develop a biosignature distinguishing EP, ongoing IUP and miscarriage. Specific Aims and Methods: We plan to develop a multiple marker bio-signature profile to aid in the diagnosis of EP. We hypothesize that a small number of markers, used in combination, will be able to distinguish an EP from IUP (combination of ongoing IUP and miscarriage) and/or can be used to distinguish a nonviable gestation (combination of EP and miscarriage) from an ongoing IUP. In Specific aim 1 we will develop, refine and validate a serum (multiple marker) test to identify EP based on putative markers of early implantation and viability. In Specific Aim 2 we will validate the potential of newly discovered biomarkers of EP to add to (or replace) those in our current multiple marker panel. In Specific aim 3 we will conduct an unbiased three-way proteomic discovery study that will identify new, lower abundance biomarker candidates that distinguish between EP, IUP and miscarriage. Summary: This proposal represents a unique opportunity to combine epidemiologic and basic science methodologies to understand and improve upon important limitations in our ability to diagnose and treat a reproductive disorder with important public health consequences. Utilizing access to a large number of geographically, racially and ethnically diverse women at risk for EP, we plan to conduct a series of multicenter case control studies using well phenotyped bio-specimens, and ultimately conduct a prospective cohort study to assess actual use in the intended patient population. The development of non invasive methods of diagnosis, such as a serum test to diagnose an EP and/or miscarriage with high accuracy, would have tremendous clinical impact.
描述(由申请人提供):这是一个高生产率、多学科、多中心项目的修订申请,该项目评价了异位妊娠(EP)和早孕失败风险女性的诊断。 早期妊娠失败是妊娠中最常见的并发症,估计25%的临床公认妊娠以流产结束,1-2%被诊断为异位妊娠(EP)。 EP是导致妊娠相关死亡的主要原因,也是孕产妇发病的主要原因。当妊娠在超声下不可见时,区分健康的持续宫内妊娠(IUP)与流产或EP构成了关键的临床挑战,因为没有其他明确的非侵入性诊断测试。目前的诊断方案可能导致所需IUP中断和/或与EP破裂相关的发病率。我们已经证明,当联合使用时,许多EP的推定生物标志物可以区分IUP和EP。 使用无偏见的蛋白质组学分析方法,我们还建立了新的生物标志物,其中一个我们已经验证:ADAM-12。 该项目的目标是扩大生物标志物的使用,以开发区分EP,持续IUP和流产的生物特征。 具体目标和方法:我们计划开发一种多标记物生物特征谱,以帮助诊断EP。 我们假设,少量的标记物,联合使用,将能够区分EP从IUP(正在进行的IUP和流产的组合)和/或可以用来区分不可行的妊娠(EP和流产的组合)从正在进行的IUP。在具体目标1中,我们将开发、完善和验证血清(多标记物)检测,以根据早期植入和存活的推定标记物识别EP。 在具体目标2中,我们将验证新发现的EP生物标志物添加到(或取代)我们目前的多标志物组中的潜力。在具体目标3中,我们将进行一项无偏见的三向蛋白质组发现研究,该研究将鉴定新的、丰度较低的生物标志物候选物,以区分EP、IUP和流产。 总结:这一建议代表了一个独特的机会,联合收割机结合流行病学和基础科学的方法,以了解和改善我们的能力,诊断和治疗生殖疾病的重要限制与重要的公共卫生后果。我们计划利用大量具有EP风险的地理、种族和人种多样性女性,使用良好表型生物标本进行一系列多中心病例对照研究,并最终进行前瞻性队列研究,以评估预期患者人群的实际使用情况。 非侵入性诊断方法的发展,例如以高准确度诊断EP和/或流产的血清测试,将具有巨大的临床影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kurt T Barnhart其他文献
Kurt T Barnhart的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kurt T Barnhart', 18)}}的其他基金
Early Double Low-Dose Aspirin to Reduce Preeclampsia and Miscarriage: a Global Approach RCT
早期双倍低剂量阿司匹林减少先兆子痫和流产:全球方法随机对照试验
- 批准号:
10711793 - 财政年份:2023
- 资助金额:
$ 66.18万 - 项目类别:
Clinical utility of novel biomarkers for prediction of early pregnancy failure
新型生物标志物预测早期妊娠失败的临床应用
- 批准号:
10563608 - 财政年份:2023
- 资助金额:
$ 66.18万 - 项目类别:
CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES
CCTN - 避孕临床试验网络 - 女性站点
- 批准号:
8933128 - 财政年份:2014
- 资助金额:
$ 66.18万 - 项目类别:
Development of a serum biosignature for ectopic pregnancy.
异位妊娠血清生物特征的开发。
- 批准号:
9268010 - 财政年份:2014
- 资助金额:
$ 66.18万 - 项目类别:
Development of a serum biosignature for ectopic pregnancy.
异位妊娠血清生物特征的开发。
- 批准号:
8631014 - 财政年份:2014
- 资助金额:
$ 66.18万 - 项目类别:
CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES
CCTN - 避孕临床试验网络 - 女性站点
- 批准号:
10329724 - 财政年份:2014
- 资助金额:
$ 66.18万 - 项目类别:
Development of a serum biosignature for ectopic pregnancy.
异位妊娠血清生物特征的开发。
- 批准号:
9473793 - 财政年份:2014
- 资助金额:
$ 66.18万 - 项目类别:
相似海外基金
Why did we start Fermenting cereals? A molecular dissection of Ancient Bread and Beer making (FABB)
我们为什么开始发酵谷物?
- 批准号:
NE/X01469X/1 - 财政年份:2023
- 资助金额:
$ 66.18万 - 项目类别:
Research Grant
Conference: International Symposium on Biomathematics and Ecology, Education and Research-BEER-XVI ASPIRE Advancing Sustainable Partnerships Integrating Research and Education
会议:生物数学与生态学、教育与研究国际研讨会-BEER-XVI ASPIRE 推进研究与教育相结合的可持续伙伴关系
- 批准号:
2318936 - 财政年份:2023
- 资助金额:
$ 66.18万 - 项目类别:
Standard Grant
Identifying Key Microorganisms and Factors to Develop Improved Spontaneous and Mixed Fermentation Beer
识别关键微生物和因素以开发改进的自发酵和混合发酵啤酒
- 批准号:
556600-2020 - 财政年份:2022
- 资助金额:
$ 66.18万 - 项目类别:
Alliance Grants
Microbial Ecology of Mixed Fermentation in Craft Beer Production
精酿啤酒生产中混合发酵的微生物生态
- 批准号:
571061-2021 - 财政年份:2021
- 资助金额:
$ 66.18万 - 项目类别:
Alliance Grants
BrewBroker’s Smart Engine for Beer Recommendation; using big data to modernise product procurement in one of the world’s oldest industries.
BrewBroker 的啤酒推荐智能引擎;
- 批准号:
10009744 - 财政年份:2021
- 资助金额:
$ 66.18万 - 项目类别:
Feasibility Studies
Identifying Key Microorganisms and Factors to Develop Improved Spontaneous and Mixed Fermentation Beer
识别关键微生物和因素以开发改进的自发酵和混合发酵啤酒
- 批准号:
556600-2020 - 财政年份:2021
- 资助金额:
$ 66.18万 - 项目类别:
Alliance Grants
KegTracker Suite: piloting a user-centric software suite for an IoT device that helps create a zero-waste supply chain in the hospitality and draught beer industry
KegTracker Suite:针对物联网设备试用以用户为中心的软件套件,有助于在酒店和生啤酒行业创建零废物供应链
- 批准号:
79115 - 财政年份:2020
- 资助金额:
$ 66.18万 - 项目类别:
Collaborative R&D
To Design and Manufacture a Mini Keg Filler, Closer & Rinser for Draught Carbonated Beer
设计和制造迷你桶灌装机,更近
- 批准号:
55472 - 财政年份:2020
- 资助金额:
$ 66.18万 - 项目类别:
Feasibility Studies
Research and development of a novel yeast management protocol for the brewing of craft beer
用于精酿啤酒酿造的新型酵母管理方案的研究和开发
- 批准号:
556425-2020 - 财政年份:2020
- 资助金额:
$ 66.18万 - 项目类别:
Applied Research and Development Grants - Level 1
Identifying Key Microorganisms and Factors to Develop Improved Spontaneous and Mixed Fermentation Beer
识别关键微生物和因素以开发改进的自发酵和混合发酵啤酒
- 批准号:
556600-2020 - 财政年份:2020
- 资助金额:
$ 66.18万 - 项目类别:
Alliance Grants